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Overexpression of trefoil factor 3 (TFF3) 
contributes to the malignant progression 
in cervical cancer cells
Zhaohu Yuan1†, Dandan Chen2†, Xiaojie Chen1, Huikuan Yang1 and Yaming Wei1*
Abstract 
Background: There remains a great need for effective therapies for cervical cancers, the majority of which are 
aggressive leaving patients with poor prognosis.
Methods and results: Here, we identify a novel candidate therapeutic target, trefoil factor 3 (TFF3) which overex-
pressed in cervical cancer cells and was associated with reduced postoperative survival. Functional studies demon-
strated that TFF3 overexpression promoted the proliferation and invasion of cervical cancer cells, and inhibited the 
apoptosis by inducing the mRNA changes in SiHa and Hela cell lines. Conversely, TFF3 silencing disrupted the prolif-
eration and invasion of cervical cancer cells, and induced the apoptosis via Click-iT EdU test, flow cytometry analysis 
and two-dimensional Matrigel Transwell analysis. Western blot analysis showed that overexpression of TFF3 repressed 
E-cadherin (CDH1) expression to promote the invasion of cervical cancer cells. Furthermore, down-regulated CDH1 
via overexpression of TFF3 was significantly up-regulated by virtue of inhibitor of p-STAT3.
Conclusions: These results suggested that TFF3 stimulated the invasion of cervical cancer cells probably by activat-
ing the STAT3/CDH1 signaling pathway. Furthermore, overexpression of TFF3 decreased the sensitivity of cervical 
cancer cells to etoposide by increasing P-glycoprotein (P-gp) functional activity. Overall, our work provides a preclini-
cal proof that TFF3 not only contributes to the malignant progression of cervical cancers and but also is a potential 
therapeutic target.
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Background
Worldwide, cervical cancer is ranked as the second most 
common cancer in women and the third leading cause 
of death from cancer in women [1, 2]. The incidence of 
cervical cancer is very high in developing countries [3]. 
Until recently, therapeutic options for hysterectomy-
resistant cervical cancers have been limited with treat-
ments largely palliative [4]. Therefore, detecting or 
preventing cervical cancers with progressions in early 
is critical, which could help to prolong patient survival. 
As we know TFF3 is a soluble peptide containing trefoil 
domain and C-terminal dimerization domain which is 
not only a novel prognostic marker but also a therapeutic 
target in various cancers, such as mammary carcinoma, 
gastric cancer and prostate carcinoma [5–8]. Upregula-
tion of TFF3 after rectal cancer chemo-radiotherapy is 
an adverse prognostic factor [9]. Furthermore, in prostate 
carcinoma cells, TFF3 reduces the sensitivity to ionizing-
radiation [10].
TFF3, behaved as an oncogene, promotes prolif-
eration and invasion, improves survival, and increases 
oncogenicity in cancer cells, such as mammary carci-
noma, gastric cancer and prostate carcinoma [5, 11]. 
TFF3 promoted epithelial tumorigenesis by induc-
ing aberrant proliferation and inhibiting apoptosis [7]. 
TFF3 also may contribute to cancer metastasis with 
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epithelial-to-mesenchymal transition (EMT) poten-
tially through the regulation of genes such as androgen 
receptor (AR), FOXA1 and human epidermal growth 
factor receptor-type 2 (HER2) [12, 13]. Moreover, TFF3, 
a secreted protein, is a valuable predictive serum bio-
marker in patients with metastatic colorectal cancer [9]. 
In cancer cells, TFF3 promotes cell migration, invasion 
and metastasis by reducing cell–cell and cell–matrix 
interactions and enhancing cell scattering in bronchiole 
or other epithelia cells [14, 15]. Up-regulation of TFF3 in 
cancer cells was accompanied by activation of multiple 
pathways including PI3K, MAPK and JAK/STAT path-
ways which were associated with cellular proliferation, 
apoptosis, migration, invasion and clonogenic survival 
[16]. Despite the evidence that TFF3 could influence vari-
ous cancer cells function in vitro, the role of TFF3 in cer-
vical cancer cells has not been examined.
In the present study, we found that TFF3 protein 
was overexpressed in cervical cancer cells and weakly 
expressed in human non-tumor keratinocytes. We 
detected up-regulated expression of TFF3 promoted 
growth, proliferation and invasion, and inhibited apopto-
sis in SiHa and Hela cells. These finding demonstrate that 
TFF3 may be a potential therapeutic target in invasive 
cervical cancers with multidrug resistance.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and 
fetal bovine serum (FBS) were obtained from GIBCO 
(Carlsbad, California, USA). Mouse anti-GPADH poly-
clonal antibody (Lot#ab37168), Rabbit anti-Trefoil Fac-
tor 3 monoclonal antibody (Lot#ab108599), Mouse 
anti-E Cadherin monoclonal antibody (Lot#ab1416), 
Mouse anti-Phospho-STAT3 monoclonal antibody 
(Lot#ab119672), Mouse anti-Total STAT3 monoclonal 
antibody (Lot#ab119672) were obtained from Abcam 
(Cambridge, UK). JSI-124 was obtained from Enzo Life 
Science (USA). Goat anti-Rabbit IgG IR Dye 800cw 
(Lot#C30626-03) and Goat anti-Mouse IgG IR Dye 
800cw (Lot#C40528-02) were from Odyssey (Licor, 
USA). Click-iT Edu imaging kit and Live/Dead Bac Light 
Viability Kit for microscopy were from Invitrogen (Carls-
bad, CA, USA).
Cell cultures and transfection
Human cervical cancer cell lines SiHa, CaSki, Hela, 
Me180 and human non-tumor keratinocyte line HaCaT 
were obtained from Nanjing KeyGen Biotech Co, Ltd 
(Nanjing,China). The cells were cultured in Dulbecco’s 
modified Eagle’s medium (GIBCO, Carlsbad, California, 
USA) containing 10% FBS in a humidified atmosphere of 
5% CO2 at 37 °C. Human TFF3 expression, TFF3 siRNA 
and CDH1 siRNA plasmid constructs have been previ-
ously described [7, 17]. Luciferase assays were performed 
as previously described [18]. Briefly, transfections were 
carried out in triplicate using 1  μg of the appropriate 
luciferase reporter construct and empty vector per trans-
fection along with 0.1  μg of Renilla luciferase construct 
as control for transfection efficiency. Luciferase activi-
ties were assayed after 24 h of transfection using the Dual 
Luciferase Assay System (Promega Corp, Madison, WI, 
USA).
RT‑PCR and semi‑quantitative RT‑PCR
Total RNA was isolated from cells using Trizol plus RNA 
Purification system as previously described [19]. DNase I 
treatment, total RNA to complementary DNA, PCR, and 
qPCR assays were performed as previously described. 
Gene expression analysis was performed as previously 
described [20] and the sequence of the primers were 
described in Additional file 1: Table S1.
Total RNA was isolated using Trizol plus RNA Puri-
fication Kit (Invitrogen, Carlsbad, CA) as previously 
described [19]. Semi-quantitative RT-PCR was per-
formed using a Super Script One Step RT-PCR kit 
(Invitrogen, Carlsbad, CA, USA). Sequences of the 
nucleotide primers for RT-PCR were: TFF3 5′-GCTG 
CCAGAGCGCTCTGCATG-3′ and 5′-AAGGTGCA 
TTTCTGCTTCCTGCAG-3′ (35 cycles; wild-type cell 
lines); β-Actin, 5′-ATGATATCGCCGCGCTCG-3′ and 
5′-CGCTCGGTGAGGATCTTCA-3′ (23 cycles). Ampli-
fied RT-PCR products were visualized on a 1.5% agarose 
gel.
In vitro invasion analysis
An in  vitro invasion assay was carried out to exam-
ine the invasion of cervical cancer cells, as previously 
described [21]. Briefly, 24-well Transwell units with 
8  µm polycarbonate nucleopore filters (Corning, NY, 
USA) were coated with 0.1  mL 0.8  mg/mL Engelbreth 
Holm-Swarm sarcoma tumor extract (EHS Matrigel) at 
room temperature for 1  h to form a genuinely recon-
stituted basement membrane. Cervical cancer cells 
(5 ×  104 cells) were placed in the upper compartment 
and 500 µL DMEM culture medium containing 10% 
fetal calf serum was added to the lower compartment. 
The Transwell plates were incubated at 37  °C for 36  h 
in a humidified atmosphere with 5% CO2 and stained 
with 10% crystal violet. Invading cells were defined as 
cells that had degraded the Matrigel and moved into the 
lower surface of the membrane. The non-invading cells 
retained on the upper surface of the membrane were 
removed by a cotton swab.
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Click‑iT EdU test
We performed the Click-iT Edu test to analyze the cervical 
cancer cell proliferation according to the manufacturer’s 
instructions. Cervical cancer cells were incubated with 
EDU for 12 h and then images were obtained to determine 
percentages of EdU-labeled cervical cancer cells.
Western blot
Cervical cancer cells lysates were separated by SDS-
PAGE, blotted onto nitrocellulose membranes, and 
probed with primary antibodies, followed by Goat anti-
rabbit or mouse IgG IR Dye 800 cw (1:15,000), respec-
tively. Images were obtained with an Odyssey Imager 
(LI-COR, Lincoln, NE, USA).
Flow cytometry and analysis
Flow cytometry analysis was performed either on FAC-
SCAN using Cell Quest software, or on MACS quant 
seven color analyzer. Data analysis was performed using 
Flow Jo software.
Total cell number
1 × 105 (SiHa and Hela) cells were seeded into 35 mm2 
falcon tissue culture dish in monolayers in 10% serum 
media in quadruplicate. On indicated days, cells were 
trypsinised and the cell number was determined using a 
haemocytometer.
Graphs and statistical analysis
All graphs were generated using Prism 4 (GraphPad Soft-
ware, Inc., California, USA). Statistical significance was 
assessed by using an unpaired two-tailed Student’s t test 
(P < 0.05 was considered as significant) using SPSS 18.0 
(SPSS, Inc., Chicago, IL, USA). Columns are the mean of 
triplicate experiments; bars ± SD. *P < 0.05, **P < 0.01.
Results
TFF3 is overexpressed in human cervical cancer cell lines
Compared with HaCaT cells, TFF3 was expressed at 
higher level in all the cervical cancer cell lines tested. To 
better reveal the functional roles of TFF3, SiHa and Hela 
cell lines were selected for next studies, in which expres-
sion of TFF3 was higher than the other two cervical can-
cer cell lines (Fig. 1a). To generate TFF3 overexpressing 
or knockdown stable cell lines, 293T cells were co-trans-
fected with retroviral constructs of pMSCV-TFF3 or 
pSIH1-TFF3 along with the respectively package system 
plasmids for 2  days. The supernatant was collected to 
infect SiHa and Hela cell lines for 2 days, and then cells 
were collected for semi quantitative PCR and Western 
blot analysis (Fig. 1b, c).
Using RT-PCR analyses, we therefore quantified the 
mRNA levels of various molecules associated with 
cellular proliferation, apoptosis, migration, invasion 
and clonogenic survival in SiHa and Hela cell lines with 
forced expression of TFF3. SiHa-TFF3 or Hela-TFF3 
cells exhibited decreased mRNA levels of BAX, TIMP2, 
CDKN2A, SERPINB5 and CDH1, relative to SiHa-vector 
cells or Hela-vector cells respectively. Concomitantly, 
SiHa-TFF3 and Hela-TFF3 cells exhibited increased 
mRNA levels of CDH2, VIM, TGFB1, TERT, SERPINE1, 
TWIST, KI67, SURVIVIN, MMP2 and MMP3, relative to 
SiHa-vector or Hela-vector cells (Fig. 1d, e). Considering 
the rapid changes in proliferative and molecular patterns 
of expression associated with the oncogenic characteris-
tics, which indicated TFF3 plays an important role in the 
malignant progression of human cervical cancer.
Overexpression of TFF3 promotes proliferation 
and survival of SiHa and Hela cells
To investigate whether TFF3 contributes to the prolifera-
tion of cervical cancer cells in vitro, we analyzed the pro-
liferation upon overexpression and knockdown of TFF3 
in SiHa and Hela cells. Overexpression of TFF3 increased 
the total cell number of SiHa and Hela cells by 1.20 fold 
and 1.26 fold respectively after 48 h. Conversely, knock-
down of TFF3 decreased the total cell number of SiHa 
and Hela cells (Fig. 2a). Furthermore, TFF3 overexpress-
ing cells (SiHa-TFF3 and Hela-TFF3 cells) showed a sta-
tistically significant increase in proliferation, as assessed 
by measuring EdU incorporation into DNA and Ki67 
expression (Fig.  2b, c). In order to verify whether the 
endogenous function of TFF3 is to promote proliferation, 
it was followed by knocking down cervical cancer cells 
expressing high level of TFF3. Specific-stranded RNA 
oligonucleotides against TFF3 or negative RNA control 
were transfected into SiHa and Hela cells. When TFF3-
specific oligonucleotides were used, a rapid down-regu-
lation of TFF3 mRNA and protein was observed (Fig. 1b, 
c). The decrease in TFF3 level resulted in a concomitant 
decrease in proliferation. Cell proliferation assays (EdU 
incorporation and Ki67 expression) showed a statisti-
cally significant decrease in proliferation when TFF3 was 
down-regulated with siRNA (Fig. 2b, c).
The number of apoptosis cells was very low in TFF3-
overexpressing cells (SiHa-TFF3 and Hela-TFF3 cells), 
but no significant differences from controls were 
observed (P > 0.05, Fig. 3a). However, the apoptotic pro-
portions in SiHa-siTFF3 and Hela-siTFF3 were signifi-
cantly increased (P < 0.01, Fig. 3a). Western Blot analysis 
demonstrated that forced expression of TFF3 reduced 
the levels of the Bax protein, whereas the Bcl-2 pro-
tein revealed only minimal increase in SiHa and Hela 
cells. The increase in Bcl-2/Bax ratio inhibits the apop-
tosis of human cervical cancer cells. Conversely, siRNA 
against TFF3 increased the expression of Bax protein and 
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reduced the levels of Bcl-2 protein (Fig. 3b). Decreasing 
the rate of Bcl-2/Bax induces mitochondria-mediated 
apoptosis in human cervical cancer cells.
CDH1 is critical for TFF3‑mediated cervical cancer cells 
invasion
Transwell invasion assays frequently were utilized to 
determine the invasiveness of cervical cancer cells 
in vitro. We therefore examined the behavior of cervical 
cancer cells with either forced or depleted expression of 
TFF3 growing on two-dimensional Matrigel. SiHa-TFF3 
cells exhibited increased ability to penetrate and migrate 
in Matrigel-coated matrix compared with SiHa-vector 
cells (100.0  ±  7.2% for control cells vs. 189.5  ±  12.4% 
for TFF3-overexpressing cells; Fig.  4a). In contrast, the 
ability of SiHa-sivector to penetrate and migrate in 
Matrigel-coated matrix significantly decreased compared 
with SiHa-vector cells (101.3 ± 8.1% for control cells vs. 
39.5 ± 4.2% for TTF3-knockdown cells; Fig. 4a). Similar 
results were obtained in Hela cells, as shown in Fig. 4a.
To further determine whether TFF3 could activate 
CDH1 expression in cervical cancer cells, TFF3-express-
ing plasmids were transiently transduced into the two 
cervical cancer cell lines. Western blot analysis was per-
formed to examine the expression of TFF3 and CDH1. 
Consistent with the results reported previously [7], 
overexpression of TFF3 in the two cell lines suppressed 
expression of CDH1 and induced CDH1 signaling was 
evidenced by increasing phosphorylation of STAT3 in 
TFF3-overexpressing cells compared with control cells 
(Fig.  4b). Conversely, TFF3 knockdown in two cervical 
cancer cell lines increased CDH1 expression mRNA level 
(Fig.  1g, h) with concomitant decrease of phosphoryla-
tion of STAT3 (Fig. 4b). These data indicated that TFF3 
could down-regulate CDH1 expression in cervical cancer 
cells.
Previous studies showed that overexpression of TFF3 
promoted cell migration and invasion [6, 7, 11]. We next 
determined whether CDH1 mediated the effect of TFF3 
on cell invasion in SiHa cells. We first utilized the CDH1-
specific siRNA to knock down CDH1 expression in the 
two cell lines. Western blot analysis showed that CDH1 
siRNAs achieved a knockdown of CDH1 expression in 
SiHa-siTFF3 cells by 70 to 80% (Fig. 4c). We performed 
cell invasion assay and found that the invasive ability in 
SiHa-siTFF3-siCDH1 cells was significantly stronger 
than that in SiHa-siTFF3 cells (Fig. 4c). In addition, trans-
fection of CDH1 siRNA also increased invasive ability of 
control cells and the percentage was significantly greater 
compared with that in SiHa-siTFF3 cells (100.0 ±  9.1% 
for control cells vs. 142.1 ± 6.2% for TFF3-overexpressing 
cells; Fig. 4c). To further confirm that the STAT3/CDH1 
signaling pathway is critical for TFF3-mediated cell 
migration and invasion, we treated TFF3-overexpressing 
or control cells with the STAT3 activity inhibitor, JSI-
124. Western blots were used to confirm the blockage 
of the CDH1 signaling pathway. As expected, the phos-
phorylation level of STAT3 was decreased with JSI-124 
treatment in TFF3-overexpressing cervical cancer cells 
(Fig. 4d). Moreover, the inhibition of STAT3/CDH1 path-
way significantly attenuated cell invasion ability in TFF3-
overexpressing cells (Fig. 4d). This is consistent with our 
hypothesis that overexpression of TFF3 could stimulate 
cell invasion through activation of the STAT3/CDH1 
signaling pathway. Similar results also were obtained in 
Hela cells.
TFF3 decreases the sensitivity of cervical cancer cells 
to etoposide by increasing P‑gp functional activity
MDR is a common clinical problem for the treatment 
of cancers in chemotherapy. Escaped cancer cells from 
chemotherapy through MDR are a major reason for 
(See figure on previous page.) 
Fig. 1 Forced expression of TFF3 in cervical cancer cells modulates the expression of malignant progression-related gene markers. a Determination 
of endogenous expression of TFF3 protein by Western blot in the cervical cancer cells lines CaSki, SiHa, Me180 and Hela and human non-tumor 
keratinocyte line HaCaT. b Semi-quantitative RT-PCR analysis was used to assess the mRNA levels of TFF3 in SiHa and Hela cells with either forced or 
depleted expression of TFF3 as described in “Methods” section. c Western blot analysis was used to assess the protein levels of TFF3 in SiHa and Hela 
cells with either forced or depleted expression of TFF3. d, e Quantitative PCR analysis quantifying the change in expression of various genes associ-
ated with malignant progression in SiHa-TFF3/Hela cells. Change in gene expression is expressed as fold difference, respectively. Fold change values 
are representative of three independent experiments
(See figure on next page.) 
Fig. 2 Correlation of TFF3 expression with the proliferation of SiHa and Hela cells. a Total cell number assays. Cells were seeded in both full-
serum (10%) and total cell number counted every 12 h. b EdU incorporation and c Ki67 flow cytometry expression assays showed a statistically 
significant increase or decrease in proliferation when TFF3 was overexpressed or knockdown respectively in SiHa and Hela cells. Results represent 
mean ± SEM. **P < 0.01. Statistical significance was assessed by using an unpaired two-tailed Student’s test (P < 0.05 was considered as significant) 
using SPSS 18.0
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clinical treatment failure [22, 23]. In this study we found 
forced expression of TFF3 in SiHa and Hela cells sig-
nificantly decreased the sensitivity to etoposide and 
inhibited the apoptosis/death by live/dead staining. Con-
versely, TFF3 knockdown increased the sensitivity of 
cervical cancer cells to etoposide and promoted apopto-
sis (Fig. 5a, b).
Rho123 is a fluorescence substrate that is applied 
to investigate P-gp functional activity. When func-
tional activity of P-gp declines, the accumulation of 
Fig. 3 Effect of TFF3 on apoptosis of SiHa and Hela cell lines. a The flow cytometry analysis and quantification analysis of apoptotic cells. Statistical 
significance was assessed by using an unpaired two-tailed Student’s t test (P < 0.05 was considered as significant) using SPSS 18.0. Columns are the 
mean of triplicate experiments; bars ±SD. **P < 0.001. b Western blot analysis was used to assess the apoptosis related protein levels in SiHa and 
Hela cells with either forced or depleted expression of TFF3
Page 8 of 13Yuan et al. Cancer Cell Int  (2017) 17:7 
Page 9 of 13Yuan et al. Cancer Cell Int  (2017) 17:7 
the Rho123 substrate within cells increases, and vice 
versa [24, 25]. Our results indicated that the amount 
of Rho123 accumulation in SiHa-TFF3 and Hela-TFF3 
cells was significantly higher than that in control cells 
(47.06  ±  5.45% for control cells vs. 73.45  ±  8.01% 
for TFF3-overexpressing cells in SiHa cell line; 
59.85  ±  7.17% for control cells vs. 90.14  ±  9.45% 
for TFF3-overexpressing cells in Hela; all P  <  0.01; 
Fig.  5c). In contrast, the amount of Rho123 accumu-
lated in SiHa-siTFF3 and Hela-siTFF3 cells significantly 
decreased compared with control cells (46.54 ±  6.32% 
for control cells vs. 33.44 ± 3.53% for TTF3-knockdown 
cells; 61.21 ± 6.84% for control cells vs. 41.43 ± 3.49% 
for TTF3-knockdown cells; all P < 0.01; Fig. 5c). How-
ever, western blot analysis showed that forced/deleted 
expression of TFF3 didn’t alter the expression level 
of P-gp. These results suggested that TFF3 increased 
intracellular accumulation of Rho123 by inhibiting 
P-gp pump function in SiHa and Hela cells and further 
decreased the sensitivity to etoposide.
Discussion
This study contributes to our understanding of the 
molecular mechanism by which overexpression of TFF3 
in human cervical cancers promotes tumor progres-
sion. The present work first found that TFF3 was overex-
pressed in cervical cancer cells and weakly expressed in 
human non-tumor keratinocytes. Several studies dem-
onstrated that TFF3 overexpression strongly correlated 
with poor prognosis in  various  tumors [26, 27], which 
indicated that TFF3 could be a potentially superior diag-
nostic marker or therapeutic target for cervical cancer. 
In this study we demonstrated that TFF3 functionally 
promoted the malignant progression of cervical cancer 
cells. Forced expression of TFF3 promoted the prolif-
eration and invasion, and inhibited the apoptosis in SiHa 
and Hela cells. Conversely, decreased expression of TFF3 
inhibited the proliferation and invasion, and induced the 
apoptosis in the two cell lines. Our data suggested that 
TFF3 stimulated an invasive phenotype in cervical can-
cer cells through STAT3 mediated repression of CDH1. 
Furthermore, we found TFF3 decreased the sensitivity 
of cervical cancer cells to etoposide by increasing P-gp 
functional activity in the two cell lines. TFF3 silencing 
increased the sensitivity of the two cell lines to etoposide 
chemotherapy.
TFF3, behaved as an oncogene, promotes cancer cell 
proliferation, survival, oncogenicity and invasion in vari-
ous cancers, such as mammary carcinoma, gastric can-
cer and prostate carcinoma [7–9]. For the first time, we 
found that TFF3 was overexpressed in cervical cancer 
cells. Elevated expression level of TFF3 has also been 
reported in the molecular apocrine subtype of estrogen 
receptor-negative mammary carcinoma characterized 
by the expression of AR, FOXA1 and a high frequency 
of HER2 expression [12, 13]. In SiHa and Hela cells, 
forced expression of TFF3 promoted cervical cancer 
cells growth, proliferation and invasion. Overexpression 
of TFF3 was caused changes in mRNA levels associated 
with the cellular proliferation, apoptosis, migration, inva-
sion and clonogenic survival. Forced expression of TFF3 
decreased mRNA expression of BAX, TIMP2, CDKN2A, 
SERPINB5 and CDH1, but increased mRNA levels of 
CDH2, VIM, TGFB1, TERT, SERPINE1, TWIST, KI67, 
SURVIVIN, MMP2 and MMP3 which closely correlated 
with increasing cell cycle progression, anti-apoptosis, 
proliferation, metastasis and invasion of cervical cancer 
cells [9, 10, 28, 29].
(See figure on previous page.) 
Fig. 4 TFF3 regulates cell and invasion of cervical cancer cells through activation of the STAT3/CDH1 signaling pathway. a Capacity of SiHa and 
Hela cells with either forced or depleted expression of TFF3 to penetrate to EHS Matrigel and Quantification analysis. b Western blot analysis was 
used to assess the levels of CDH1, p-STAT3 andSTAT3 in cervical cancer cells with either forced or depleted expression of TFF3. c Effect of CDH1-
specific siRNA on invasion of SIHA or HELA with depleted expression of TFF3. CDH1-specific siRNA increased the invasive percentage SiHa and Hela 
cells with depleted expression of TFF3. d Western blot analysis was used to assess the levels of CDH1 in SiHa or Hela cells with forced expression 
of TFF3on exposure to JSI-124 (0.2 μM) inhibitor and Effect of p-STAT3 on invasion of SiHa or Hela. Statistical significance was assessed by using 
an unpaired two-tailed Student’s t test (P < 0.05 was considered as significant) using SPSS 18.0. Columns are the mean of triplicate experiments; 
bars ±SD. **P < 0.001
(See figure on next page.) 
Fig. 5 TFF3 decreased sensitivity of cervical cancer cells to etoposide by increasing P-gp functional activity (a) Cultures were stained with the live/
dead stain. The cervical cancer cells were treated with 10 μmol/L etoposide for 24 h. Live cervical cancer cells with intact cell membranes stain 
fluorescent green, whereas cells with damaged membranes and dead cells stain fluorescent red (×200). b Total cell number assays of cervical cancer 
cells treated with etoposide (10 μmol/L) on 24 h. c The amount of Rho123 accumulated in cervical cancer cells was detected by flow cytometry to 
reflect P-gp function and Quantification analysis of Rho 123 positive cells. d The effect of TFF3 on expression of drug resistance-related protein, P-gp. 
Statistical significance was assessed by using an unpaired two-tailed Student’s t test (P < 0.05 was considered as significant) using SPSS 18.0. Columns 
are the mean of triplicate experiments; bars ±SD. **P < 0.001
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In the cervix cells, TFF3 expression was detected sig-
nificantly higher level in cervical cancer cells than in 
human non-tumor keratinocytes. The results presented 
here clearly demonstrated that TFF3 overexpression 
accelerated cell cycle progression and a decrease in TFF3 
levels slowed the progression of cells. In addition, TFF3 
levels correlated with the proliferative potential of cervi-
cal cancer cells as revealed by correlation between TFF3 
and Ki67 levels in  vivo. As an oncogene, TFF3 is quali-
fied with various functions that could impinge on nor-
mal cell proliferation. It is known that TFF3 induces the 
expressions of AR, FOXA1, HER2 and basic fibroblast 
growth factor (bFGF) in vitro in various cancers such as 
breast cancer and melanoma cells [12, 13, 30]. Our study 
revealed that overexpression of TFF3 had no effect on 
apoptosis in SiHa and Hela cells. But siRNA-mediated 
depletion of TFF3 induced the apoptosis of cervical can-
cer cells by decreasing anti-apoptotic protein, Bcl-2 and 
increasing pro-apoptotic protein, Bax. The ratio of anti-
apoptotic and pro-apoptotic members within the Bcl-2 
family plays an important role to determine cell fate 
[31–33].
It is well known that TFF3 is associated with invasion 
and metastasis which plays very important roles in pro-
gression of tumors. It was first discovered TFF3 might 
regulate migration via a Twist-dependent pathway in 
gastric cells [6], which was an indispensable step in the 
process of cell invasion. TFF3 participated in cancer inva-
sion metastasis in breast cancer through repression of 
CDH1 mediated by STAT3 [7]. CDH1, as a tumor sup-
pressor glyco-protein, is one of the major constituents of 
cell adhesion complexes and mediates calcium-depend-
ent cellular interactions in epithelial cells, which plays a 
key role in the establishment of adherent type junctions 
[34, 35]. Loss of CDH1 expression, or CDH1 dysfunc-
tion, contributes to the loss of cell–cell interaction which 
stimulates cancer cells to gain an invasive cell phenotype 
and metastasis [36–38]. By two-dimensional Matrigel 
Transwell analysis we found TFF3 was critical for cervical 
cancers to involve invasion. Moreover, we observed that 
TFF3 repressed the expression of CDH1 to promote cell 
invasion in cervical cancer cells. Western blot analysis 
showed that siRNA against TFF3 increased the expres-
sion of CDH1 and decreased phosphorylation of STAT3 
which up-regulated the expression of CDH1. Further-
more, up-regulated CDH1 via overexpression of TFF3 
was significantly down-regulated by virtue of inhibitor 
of p-STAT3, JSI-124, which was similar to those reported 
by Pandey [7]. Our results suggested that TFF3 stimu-
lates invasion of cervical cancer cells probably by, at least 
partially, activating the STAT3/CDH1 signaling pathway. 
CDH1 is a downstream protein of TFF3 and may be a key 
modulator of TFF3-mediated cervical cancer invasion.
Surgery combined with chemotherapy or radiother-
apy is still the optimal treatment for cervical cancer 
while MDR causes the cervical cancer cells to be resist-
ant to chemotherapeutic drugs resulting in chemo-
therapy failure [39–41]. Previously study showed that 
up-regulation of TFF3 after rectal cancer chemo-radi-
otherapy is an adverse prognostic factor. The physi-
ological role of TFF3 in restoring the mucosa during 
neo-adjuvant chemotherapy could be interfering with 
treatment efficacy by increase neo-adjuvant chemo-
therapy resistance [9]. In this study, we showed that 
TFF3 decreased the sensitivity of cervical cancer cells 
to etoposide by increasing P-gp functional activity and 
had no effect on the expression of P-gp. Drug resistance 
to chemotherapy is mediated mainly by the overex-
pression of P-gp which is a phosphorylated transmem-
brane glycoprotein pump with ATP enzyme activity 
encoded by mdr-1 gene [42, 43]. P-gp exerts an impact 
on drug distribution by pumping a substantial amount 
of compounds from intracellular to extracellular sites, 
especially hydrated cation compounds. In addition, 
overexpression of TFF3 decreased the sensitivity of 
cancer cells to chemotherapy by mediating Bcl-2 [44, 
45].
Conclusions
In this study our evidence presented that TFF3 is 
expressed between human non-tumor keratinocyte line 
and cervical cancer cell lines distinctively, inducing pro-
liferative activity and malignant progression of cervical 
cancer patients, strongly supporting a role for this gene 
in cervical carcinogenesis.
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